Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2

Conditions

Carcinoma, Renal Cell 5Kidney Neoplasms 3Melanoma 2Prostatic Neoplasms 1

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × bryostatin 1 × Genitourinary × Clear all
NCT00006022 2015-12-14

Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00112476 2013-05-03

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡